Download Files:
Oclacitinib
$84 – $588
Products Details
Product Description
– Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).
Web ID
– HY-13577
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C15H23N5O2S
References
– [1]Gonzales AJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.|[2]Fukuyama T, et al. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis. J Pharmacol Exp Ther. 2015 Sep;354(3):394-405.|[3]Cosgrove SB, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013 Oct;24(5):479-e114.
CAS Number
– 1208319-26-9
Molecular Weight
– 337.44
Compound Purity
– 99.23
SMILES
– CN([C@H]1CC[C@@H](CC1)CS(NC)(=O)=O)C2=C3C(NC=C3)=NC=N2
Clinical Information
– Launched
Research Area
– Inflammation/Immunology
Solubility
– DMSO : ≥ 44 mg/mL
Target
– JAK
Isoform
– JAK1;JAK2;JAK3;Tyk2
Pathway
– Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
